ALNYvsUTHR
Alnylam Pharmaceuticals IncvsUnited Therapeutics Corp. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.
Alnylam Pharmaceuticals Inc
$313.79
-19.78%
United Therapeutics Corp
$567.16
+13.36%
60-day price, rebased to 100
Round-by-round
Valuation upside
-30.50% vs -9.50% to DCF fair value
Balance-sheet strength
Altman Z 5.77 vs 20.69
Fundamental quality
Piotroski 6.00 vs 7.00 (of 9)
Growth + margins
Rule-of-40 77.70 vs 43.10
60-day momentum
-7.18% vs +21.27% price return
Market-cap liquidity
$41.4B vs $23.1B
Verdict
Across6categories,UTHRtakes the edge with4wins to2. Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.
Backtest a strategy onALNYorUTHR
Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.